```
=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              180.35     180.56

FILE 'CAPLUS' ENTERED AT 08:05:37 ON 20 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 Feb 2007  VOL 146 ISS 9
FILE LAST UPDATED: 19 Feb 2007  (20070219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3            7 L2

=> d fbib ed abs hitstr tot
```



chain nodes :
19 20 21 22 23 24 25 26 27 28 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
5-19 6-22 8-20 10-25 11-26 12-27 14-23 16-30 17-29 18-28 19-20 20-21
22-23 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-19 6-22 7-8 7-12 8-9 8-20 9-10 10-11 10-25
11-12 11-26 12-27 13-14 13-18 14-15 14-23 15-16 16-17 16-30 17-18 17-29
18-28 19-20 20-21 22-23 23-24

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 ful
FULL SEARCH INITIATED 08:05:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       342 TO ITERATE

100.0% PROCESSED      342 ITERATIONS                                  4 ANSWERS
SEARCH TIME: 00.00.01

L2             4 SEA SSS FUL L1

=> d tot
```

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 653571-88-1 REGISTRY
ED Entered STN: 24 Feb 2004
CN Benzamide, N,N'-1,2-cyclohexanediylbis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)
MF C20 H22 N2 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 653571-86-9 REGISTRY
ED Entered STN: 24 Feb 2004
CN Benzamide, N,N'-(1R,2R)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GTP 3
FS STEREOSEARCH
MF C20 H22 N2 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 653571-85-8 REGISTRY
ED Entered STN: 24 Feb 2004
CN Benzamide, N,N'-(1R,2S)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GTP 2
FS STEREOSEARCH
DR 808196-21-6
MF C20 H22 N2 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 651302-04-4 REGISTRY
ED Entered STN: 18 Feb 2004
CN Benzamide, N,N'-1,2-phenylenebis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)
MF C20 H16 N2 O8
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:731634 CAPLUS
DN 143:211724
TI Preparation of amide derivatives having phenol moiety as antibacterial agents
IN Suzuki, Joji; Azuma, Yosuke
PA Mitsui Chemicals Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005213194	A	20050811	JP 2004-21740	20040129
			JP 2004-21740	20040129

OS MARPAT 143:211724
ED Entered STN: 12 Aug 2005
GI



I

AB Title compds. I [A = (un)substituted alkyl, (un)substituted phenyl; R1, R2, R3 = H, alkyl, etc.; R4 = H, hydroxy-protecting group] were prepared For example, amidation of 3,4-bis(benzyloxy)benzoic acid with 1,3-phenylenediamine followed by hydrogenolysis using Pd/C afforded N,N'-bis(3,4-dihydroxybenzoyl)-1,3-phenylenediamine (II) in 55.4% overall yield. In antibacterial testing, the MIC value of compound II against Escherichia coli was 250 μg/mL. Compds. I are claimed as antibacterial agents.
IT 651302-04-4 653571-85-8 653571-86-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amide derivs. having phenol moiety as antibacterial agents)
RN 651302-04-4 CAPLUS
CN Benzamide, N,N'-1,2-phenylenebis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 653571-85-8 CAPLUS
CN Benzamide, N,N'-(1R,2S)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 653571-86-9 CAPLUS
CN Benzamide, N,N'-(1R,2R)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:522073 CAPLUS
DN 143:38380
TI Benzenediamine derivatives as topoisomerase inhibitors
IN Suzuki, Keitaro; Okawara, Tadashi
PA Mercian Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005154342	A	20050616	JP 2003-395361	20031126
			JP 2003-374456 A	20031104

OS MARPAT 143:38380
ED Entered STN: 17 Jun 2005
GI



I

AB Benzenediamine derivs. (I; R1, R2, R3 = H, OH, OAc) prepared from benzoyl halides are claimed as DNA replication-related topoisomerase I and II inhibitors and antitumor agents. I were prepared and their topoisomerase inhibiting activities were tested.
IT 651302-04-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzenediamine derivs. as topoisomerase inhibitors)
RN 651302-04-4 CAPLUS
CN Benzamide, N,N'-1,2-phenylenebis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:631765 CAPLUS
DN 141:173963
TI Nitric oxide synthase inhibitors containing ring structures
IN Watanabe, Masamichi; Ino, Akira; Yasui, Takeshi; Kato, Kenji
PA Shionogi and Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2004217600	A	20040805	JP 2003-9668	20030117
			JP 2003-9668	20030117

ED Entered STN: 06 Aug 2004
GI



I

AB Nitric oxide synthase (NOS) inhibitors having the formula (I) (ring A is optionally substituted hydrocarbon ring or the hetero ring (except parazolopyrimidine); X = single bond, -O-, -(CR2R3)mO-, -O(CR2R3)m-, -N(R4)-, -CON(R4)(CR2R3)mO-, -O(CR2R3)mCON(R4)-, -N(R4)(CR2R3)mO-, -O(CR2R3)mN(R4)-, -O(CR2R3)mO-, -COO(CR2R3)mO-, or -CON(R4)N(R5)-; R1 = hydrogen, lower alkyl, or aryl lower alkyl; R2 and R3 = hydrogen or lower alkyl; R4 and R5 = hydrogen, lower alkyl, or carbamoyl; n is integer 1-3, m is integer 1-5), are disclosed. Preferably, the ring A is optionally substituted cyclo alkane, bicyclo alkane, benzene, tetrahydropyran, dihydropyran, THF, pyrrolidine, piperidine, piperazine, pyridine, or pyrimidine. Synthesis of those compds. are described in examples. Inhibitory effect of some of those compds. were tested on two isoforms of NOS, nNOS and iNOS. Compds. of this invention showed particularly strong inhibition of iNOS.
IT 651302-04-4P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(nitric oxide synthase inhibitors containing ring structures)
RN 651302-04-4 CAPLUS
CN Benzamide, N,N'-1,2-phenylenebis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:483478 CAPLUS
DN 142:48469
TI Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors
AU Kazi, Aslamuzzaman; Wang, Zhigang; Kumar, Naveen; Falsetti, Samuel C.; Chan, Tak-Hang; Dou, Q. Ping
CS University of South Florida, Tampa, FL, 33612, USA
SO Anticancer Research (2004), 24(2B), 943-954
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
ED Entered STN: 16 Jun 2004
AB Background: Cancer-related mol. targets of green tea polyphenols, such as (-)-epigallocatechin-3-gallate [(-)-EGCG], remain unknown. We previously showed that (-)-EGCG is a potent and specific inhibitor of the proteasomal
chymotrypsin-like activity in vitro and in vivo. Materials and Methods: EGCG amides and five simple analogs were prepared by enantioselective synthesis. Proteasome inhibition in vitro was measured by fluorogenic substrate assay and in vivo by accumulation of proteasome target proteins (p27, I.vkappa.Ba and Bax). Inhibition of tumor cell proliferation was determined by G1 arrest, DNA fragmentation and colony formation inhibition.
Results: EGCG analogs with modifications in the A-ring, C-ring or ester bond inhibit the chymotrypsin-like activity of purified 20S proteasome with altered potencies. However, these compds. were able to potently inhibit the proteasome activity in vivo and also suppress colony formation
of prostate cancer LNCaP cells. Some compds. caused G1 arrest and DNA fragmentation in leukemia Jurkat T cells. However, these EGCG analogs caused no or little proteasome inhibition in normal or nontransformed cells. Conclusion: The A-ring and gallate ester/amide bond are essential for the proteasome-inhibitory function of (-)-EGCG.
IT 653571-85-8, GTP 2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GTP-2 containing cis-diamides is slightly less potent than GTP-1 in human
prostate cancer cell line LNCaP)
RN 653571-85-8 CAPLUS
CN Benzamide, N,N'-(1R,2S)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 653571-86-9, GTP 3

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GTP-3 was more potent than GTP-1, increased p27, IκB-α, Bax and polyubiquitinated protein in LNCaP cells)
RN 653571-86-9 CAPLUS
CN Benzamide, N,N'-(1R,2R)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:214105 CAPLUS
DN 140:423448
TI Inhibitory activities against topoisomerase I & II by polyhydroxybenzoyl amide derivatives and their structure-activity relationship
AU Abdel-Aziz, Mohamed; Matsuda, Kazuya; Otsuka, Masami; Uyeda, Masaru; Okawara, Tadashi; Suzuki, Keitarou
CS Faculty of Medical and Pharmaceutical Sciences, Department of Bioorganic Medicinal Chemistry, Kumamoto University, Kumamoto, 862-0973, Japan
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(7), 1669-1672
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:423448
ED Entered STN: 18 Mar 2004
AB O-, m-, p-Phenylenediamines having 2,3,4-trihydroxy, 3,4-dihydroxy, and 4-hydroxybenzoyl moieties were prepared and their inhibitory activities were measured against topoisomerase I and II. More hydroxy groups on two aromatic rings increased the activities.
Bis(trihydroxybenzoyl)-o-phenylenediamide showed IC50 0.90 and 0.09 μM against topoisomerase I and II, resp. Compds. with hydroxy groups protected by acetyl moiety still had the activities. Fewer hydroxy groups resulted in decreased activities. Benzothiazole derivs. also indicated the activities.
IT 651302-04-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and inhibitory activities against topoisomerase I & II of polyhydroxybenzoyl amides)
RN 651302-04-4 CAPLUS
CN Benzamide, N,N'-1,2-phenylenebis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:97546 CAPLUS
DN 140:139477
TI Telomerase inhibitors containing o-phenylenediamines and pharmaceuticals containing them
IN Tsuruo, Takashi; Suzuki, Tsuneji; Tsuchiya, Katsutoshi; Shimazaki, Toshiyuki
PA Mitsui Chemicals Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004035485	A	20040205	JP 2002-196076	20020704
			JP 2002-196076	20020704

OS MARPAT 140:139477
ED Entered STN: 06 Feb 2004
GI



I

AB The inhibitors, useful as anticancer agents, contain o-phenylenediamines I
[Z = substituted Ph, heterocyclyl; R1-R4, R7 = H, OR5, (un)substituted amino, NO2, CO2H, C1-5 alkoxycarbonyl, halo, (un)substituted sulfonyl; R1 and/or R2 = OR5; R5 = H, protective group; R6 = H, C1-5 (un)substituted alkyl, benzyl] or their salts. 3,4,5-Tribenzyloxybenzoic acid was chlorinated, amidated by o-phenylenediamine, and hydrogenated to give I (R1 = R4-R7 = H, R2 = R3 = OH, Z = 3,4,5-trihydroxyphenyl), which in vitro inhibited telomerase with IC50 of 0.64 μM.
IT 651302-04-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(telomerase inhibitors containing o-phenylenediamines for anticancer agents)
RN 651302-04-4 CAPLUS
CN Benzamide, N,N'-1,2-phenylenebis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:92256 CAPLUS
DN 140:163490
TI Preparation of cyclohexanediamines and their use as antitumor agents and telomerase inhibitors
IN Tsuruo, Takashi; Suzuki, Tsuneji; Tsuchiya, Katsutoshi; Shimazaki, Toshiyuki
PA Mitsui Chemicals Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004035484	A	20040205	JP 2002-196058	20020704
			JP 2002-196058	20020704

OS MARPAT 140:163490
ED Entered STN: 05 Feb 2004
GI



I

AB Title compds. I [R1-R9 = H, OH, NH2, NO2, CO2H, C1-5 alkoxycarbonyl, etc.; R1 or R2 = OH; at least one of R6-R9 = H; R10 = H, C1-5 (un)substituted alkyl, PhCH2] or their pharmacol. acceptable salts are prepared Thus, 3,4,5-tri(benzyloxy)benzoic acid was treated with oxalyl chloride, amidated with 1,2-cis-cyclohexanediamine, and hydrogenated to give N,N'-bis(3,4,5-trihydroxybenzoyl)-1,2-cis-cyclohexanediamine, which inhibited telomerase with IC50 value of 2.9 μM.
IT 653571-85-8P 653571-86-9P 653571-88-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclohexanediamine amides as antitumor agents and telomerase inhibitors)
RN 653571-85-8 CAPLUS
CN Benzamide, N,N'-(1R,2S)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 653571-86-9 CAPLUS
CN Benzamide, N,N'-(1R,2R)-1,2-cyclohexanediylbis[3,4,5-trihydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 653571-88-1 CAPLUS
CN Benzamide, N,N'-1,2-cyclohexanediylbis[3,4,5-trihydroxy- (9CI) (CA INDEX NAME)